CNS Pharmaceuticals, Inc.

NASDAQ: CNSP · Healthcare · Biotechnology

PublicHQ Houston, TX · HarrisCIK 0001729427Reports USD

#1 of 1,394 Healthcare companies by revenue

EA Score

——

FH 22DQ —GM —SS 27

v0.1 · 35/100 weight · pillars only

↑ balance-sheet leverage, market scale · ↓ Piotroski F, return on equity

Methodology →

Revenue TTM

Rev growth YoY (TTM)

needs 8 qtrs

Net income (FY)

-$15.9M

Employees

Market cap

$2.9M

Financials — latest annual

SEC EDGAR · USD-normalized

ConceptUSDNativeFY

Net income-$15.9M-$15.9M2025

Operating income-$16.0M-$16.0M2025

Total assets$8.6M$8.6M2025

Liabilities$4.1M$4.1M2025

Equity$4.5M$4.5M2025

Revenue by segment

No segmentation disclosed for this filer. n/a

The read

CNS Pharmaceuticals, Inc. earned -$15.9M in FY2025 net income.

Peers · Healthcare

Delota Corp.——Medican Enterprises, Inc.——Veltex Corporation49D Dogwood Therapeutics, Inc.——

Neighbors

Harris →

Exxon Mobil Corporation$332.2B76B+Chevron Corporation$184.4B70B ConocoPhillips$51.8B74B Quanta Services, Inc.$28.5B68B Waste Management, Inc.$25.2B82B+Enterprise Products Partners L.P.$52.6B74B

Key facts

CEORami Levin

SectorHealthcare

IndustryBiotechnology

HeadquartersHouston, TX

ExchangeNASDAQ: CNSP

Employees4

IPO date2019-11-08

Latest filings

8-K2026-07-02 10-Q2026-05-14 8-K2026-05-04 10-K2026-03-31 8-K2026-03-11 8-K2026-03-02 8-K2026-02-17 8-K2025-12-17

Financials: SEC EDGAR (XBRL), USD-normalized per IAS 21 · TTM/quarterly + segments: FMP from filed disclosures · Filings: EDGAR submissions. County headcount and EA Score are in progress — see docs/DATA_GAPS.md.